Eisenhower

[Eisenhower @specwiz]

@investseekers Sorry, I meant could you post the data you’re looking at

[Eisenhower @specwiz]

@ResearchPulse1 @Ashwinreads How do you get these numbers?

[Eisenhower @specwiz]

@RNAiAnalyst Makary is still FDA Commissioner, and he went on live TV and spoke negatively about this program… And now Street assumes they’ll replace Prasad with someone less controversial and that they’ll all change their tune on $QURE? Doubtful

[Eisenhower @specwiz]

@SecKennedy Just words, absolutely nothing behind it. Show me one Pharma that incorporated a meaningful headwind in their full year revenue guidance following the MFN agreement

[Eisenhower @specwiz]

@SteveWagsInvest No reason for them to be a follower in this category (not to mention they got out of diabetes years ago). Plenty of good assets out there, however Shibutani will lead Chris to do some moronic deal and their entire stock narrative will flip to obesity

[Eisenhower @specwiz]

@DoodadDoctor Too far along? ITCI got acquired 5 years post launch with an IP runway into the early/mid 2030s… I think BMRN is a better example of a company that is too far along to be acquired, but ASND is essentially 1 years old with a ton of revenue and EBIT potential ahead…

[Eisenhower @specwiz]

$UCB - Mgmt signaling to the Street to “stop taking numbers up” with this guide today… Bim’ decelerating big time (Rx’s not even growing QoQ), rest of the biz not exciting, galvo’ in another dose-finding Phase IIa (this isn’t launching til 2032), donza’ not moving forward…

[Eisenhower @specwiz]

@TTRAmyloid You’re seeing Vyvgart get used 85% of the time behind IVIg (the only approved therapy in CIDP). Isn’t that the same logic?

[Eisenhower @specwiz]

@TTRAmyloid So Uplizna dead in the water?

[Eisenhower @specwiz]

$ALKS - Pops is OUT! A true Pharma veteran is stepping down as CEO after 30+ years. How often do you see a CEO step down right before the company’s biggest clinical, regulatory and commercial card flips in almost a decade (or arguably ever)? Good luck, Blair. You’ll need it…

[Eisenhower @specwiz]

As a long time $JAZZ bear, I couldn’t think of a better time to be long this stock

[Eisenhower @specwiz]

And just like that, $JAZZ is back… A 10%+ move in the stock today crushed shorts hoping for a weak guide (re: oxybate pressure on volume & price), and that overhang is now behind us. Management heavily emphasized BD in rare disease on the call - let’s see that card flip over…

[Eisenhower @specwiz]

BD is sensible given uncertainties in the oxybate market - some out there are convinced oxybate and OX2s are going to be used in combination - though it behooves the board to de-risk future revenue growth in the event the market moves towards OX2 monotherapy

[Eisenhower @specwiz]

Not to mention zani’ couldn’t be launching at a better time… In the event you get meaningful oxybate erosion - zani curbs it with the GEA launch. In the event you don’t, BD to further fuel revenue growth… We’re looking at either healthy revenue growth or accelerated growth...

[Eisenhower @specwiz]

All of this being said, the board has demonstrated sheer incompetence on capital allocation in recent years - $CTLT being a prime example - and this new CEO is beyond over his head. Can we trust they’d do a smart deal? I think that’s hard to feel totally confident in…

[Eisenhower @specwiz]

While it’s been years since we’ve seen transformational mega deals in LC Pharma (being they rarely demonstrate success), a very desperate $NVO is likely in pursuit of the next mega deal amid the looming sema’ cliff and lack of revenue diversification - $ALNY the best pick?

[Eisenhower @specwiz]

$ARGX, while rare disease, feels out of the NVO wheelhouse, with $INSM being completely out of bounds… They ideally need the type of transaction that $MRK found in $XLRN, though those are few are far between. $ASND makes total sense, but isn’t enough to fill the entire hole

[Eisenhower @specwiz]

and $JAZZ beginning to break free from the oxybate overhang as revenue diversification and M&A continues

[Eisenhower @specwiz]

Enthusiasm to get behind the mid-cap value traps in biopharma - namely $BMRN, $NBIX, and $JAZZ - is building. None of these without decent controversy, but can this basket of cheap names actually begin to work in this all-forgiving tape? Feels like it…